Literature DB >> 27012525

Quantitative Analysis of Human Neonatal Fc Receptor (FcRn) Tissue Expression in Transgenic Mice by Online Peptide Immuno-Affinity LC-HRMS.

Yao-Yun Fan1, Hendrik Neubert1.   

Abstract

Neonatal Fc receptor (FcRn) is the homeostatic receptor responsible for the long half-life of endogenous IgG by protecting it from lysosomal degradation. Understanding systemic FcRn tissue expression is important to predict and design the half-life of therapeutic antibodies and Fc-coupled biotherapeutics. To this end, we measured human FcRn (hFcRn) tissue expression in Tg32, a human FcRn knock-in transgenic mouse model, for which a strong correlation of drug clearance to humans has been demonstrated. Building an hFcRn tissue expression profile in Tg32 was enabled by the development of a tissue preparation procedure composed of bead-based protein extraction and protein precipitation using acetone followed by pellet digestion with trypsin. Digests were then loaded onto an online peptide immuno-affinity flow configuration hyphenated with reversed phase nanoflow chromatography and coupled with high resolution mass spectrometry to quantify hFcRn derived peptides. The workflow allowed bypassing some of the challenges typically associated with membrane protein analysis. We demonstrated acceptable precision and bias for measuring hFcRn in tissue matrices, typically within 20% coefficient of variation and relative error. We also report hFcRn expression in several Tg32 tissues. We anticipate that establishing a quantitative approach for hFcRn in tissues will enable the systematic measurement of hFcRn concentrations to further increase the accuracy of physiologically based pharmacokinetic (PBPK) models for PK prediction of Fc-containing biotherapeutics. This is anticipated to improve the translation of pharmacokinetic data from preclinical model systems to humans.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27012525     DOI: 10.1021/acs.analchem.5b03900

Source DB:  PubMed          Journal:  Anal Chem        ISSN: 0003-2700            Impact factor:   6.986


  14 in total

1.  Distribution of FcRn Across Species and Tissues.

Authors:  Sari Latvala; Bjoern Jacobsen; Michael B Otteneder; Annika Herrmann; Sven Kronenberg
Journal:  J Histochem Cytochem       Date:  2017-04-12       Impact factor: 2.479

2.  Tissue expression profile of human neonatal Fc receptor (FcRn) in Tg32 transgenic mice.

Authors:  Yao-Yun Fan; Lindsay B Avery; Mengmeng Wang; Denise M O'Hara; Sheldon Leung; Hendrik Neubert
Journal:  MAbs       Date:  2016-04-22       Impact factor: 5.857

3.  Hematopoietic cells as site of first-pass catabolism after subcutaneous dosing and contributors to systemic clearance of a monoclonal antibody in mice.

Authors:  Wolfgang F Richter; Gregory J Christianson; Nicolas Frances; Hans Peter Grimm; Gabriele Proetzel; Derry C Roopenian
Journal:  MAbs       Date:  2018-05-09       Impact factor: 5.857

4.  Quantification of Neonatal Fc Receptor and Beta-2 Microglobulin in Human Liver Tissues by Ultraperformance Liquid Chromatography-Multiple Reaction Monitoring-based Targeted Quantitative Proteomics for Applications in Biotherapeutic Physiologically-based Pharmacokinetic Models.

Authors:  Xiazi Qiu; Michael Zhuo Wang
Journal:  Drug Metab Dispos       Date:  2020-07-28       Impact factor: 3.922

5.  Utility of a human FcRn transgenic mouse model in drug discovery for early assessment and prediction of human pharmacokinetics of monoclonal antibodies.

Authors:  Lindsay B Avery; Mengmeng Wang; Mania S Kavosi; Alison Joyce; Jeffrey C Kurz; Yao-Yun Fan; Martin E Dowty; Minlei Zhang; Yiqun Zhang; Aili Cheng; Fei Hua; Hannah M Jones; Hendrik Neubert; Robert J Polzer; Denise M O'Hara
Journal:  MAbs       Date:  2016-05-27       Impact factor: 5.857

6.  Computer-assembled cross-species/cross-modalities two-pore physiologically based pharmacokinetic model for biologics in mice and rats.

Authors:  Armin Sepp; Guy Meno-Tetang; Andrew Weber; Andrew Sanderson; Oliver Schon; Alienor Berges
Journal:  J Pharmacokinet Pharmacodyn       Date:  2019-05-11       Impact factor: 2.745

Review 7.  Physiologically-based modeling of monoclonal antibody pharmacokinetics in drug discovery and development.

Authors:  Patrick M Glassman; Joseph P Balthasar
Journal:  Drug Metab Pharmacokinet       Date:  2018-11-22       Impact factor: 3.614

8.  Low muscle mass at initiation of anti-TNF therapy for inflammatory bowel disease is associated with early treatment failure: a retrospective analysis.

Authors:  D Q Holt; P Varma; B J G Strauss; A S Rajadurai; G T Moore
Journal:  Eur J Clin Nutr       Date:  2017-02-22       Impact factor: 4.016

9.  Impact of altered endogenous IgG on unspecific mAb clearance.

Authors:  Saskia Fuhrmann; Charlotte Kloft; Wilhelm Huisinga
Journal:  J Pharmacokinet Pharmacodyn       Date:  2017-04-24       Impact factor: 2.745

10.  Structure-Based Design and Discovery of a Long-Acting Cocaine Hydrolase Mutant with Improved Binding Affinity to Neonatal Fc Receptor for Treatment of Cocaine Abuse.

Authors:  Fang Zheng; Xiabin Chen; Kyungbo Kim; Ting Zhang; Haifeng Huang; Shuo Zhou; Jinling Zhang; Zhenyu Jin; Chang-Guo Zhan
Journal:  AAPS J       Date:  2020-03-18       Impact factor: 4.009

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.